Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.35 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.35 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.35 |
| ▸ | MC4R | P32245 | 2/20 | 0.33 |
| ▸ | CA1 | P00915 | 2/20 | 0.32 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19481207 | 0.98 | GNAI3 (0.38) | KDM2BOPRM1GNAI3GNAO1GNAI1 | |
| SCHEMBL19101360 | 0.98 | GNAI3 (0.38) | KDM2BOPRM1GNAI3GNAO1GNAI1 | |
| SCHEMBL803602 | 0.94 | KDM2B (0.39) | KDM2BOPRM1GNAI3GNAO1GNAI1 | |
| SCHEMBL21499827 | 0.93 | KDM2B (0.36) | KDM2BOPRM1GNAI3GNAO1GNAI1 | |
| SCHEMBL9070252 | 0.91 | OPRM1 (0.44) | KDM2BOPRM1CA1SPHK1LMNA | |
| SCHEMBL20283927 | 0.91 | KDM2B (0.35) | KDM2BOPRM1GNAI3GNAO1GNAI1 | |
| SCHEMBL11870424 | 0.89 | OPRM1 (0.42) | KDM2BOPRM1SPHK1LMNATSHR | |
| SCHEMBL3411263 | 0.89 | OPRM1 (0.42) | KDM2BOPRM1SPHK1LMNATSHR | |
| SCHEMBL13881902 | 0.85 | MC4R (0.36) | OPRM1MC4RKDM4ETSHRMCL1 | |
| SCHEMBL28122630 | 0.84 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210230538-A1 | USES OF KINASE INHIBITORS FOR INDUCING AND MAINTAINING PLURIPOTENCY | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2021-07-29 | — | — | US | disclosed |
| US-20100029636-A1 | Lck inhibitors | NOVARTIS AG (CH) | 2010-02-04 | — | — | US | disclosed |
| CN-101516888-A | Pyrazolo [1, 5-a] pyrimidine derivatives and their therapeutic use | NOVARTIS AG (CH) | 2009-08-26 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029636-A1 | Lck inhibitors | LCK, ZAP70, FYN | KDM2B 821/4885OPRM1 4156/4885GNAI3 858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.